RNTX (Rein Therapeutics) Buyback Yield %: -3.65 (As of Jul. 09, 2026)


RNTX Rein Therapeutics Inc RNTX
30 GF Score
Price $1.00
! 1 Warning Sign
View Full Analysis

What is Rein Therapeutics Buyback Yield %?

Rein Therapeutics RNTX +2.87% 30 Buyback Yield % is -3.65 as of Jul. 09, 2026. GuruFocus rates RNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 741 Biotechnology companies, Rein Therapeutics ranks better than 63.16% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Rein Therapeutics's current buyback yield was -3.65%.

Rein Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Rein Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rein Therapeutics Buyback Yield % Chart

Rein Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -109.01 0.00 0.00 -21.36 -10.68

Rein Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.22 -0.23 -6.82 -10.68 -8.32

RNTX vs IBIO, RANI, OSTX: Buyback Yield % Comparison

For the Biotechnology subindustry, Rein Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rein Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Rein Therapeutics's Buyback Yield % falls into.


RNTX
30GF Score
Rein Therapeutics Inc RNTX
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rein Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Rein Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 3.414) / 31.958
=-10.68%

Rein Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 3.031) / 36.4507
=-8.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -3.65 mean?
Rein Therapeutics (RNTX) has a Buyback Yield % of -3.65 as of Jul. 09, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Rein Therapeutics and its competitors. According to the industry distribution chart, Rein Therapeutics ranks #273 out of 741 companies in the Biotechnology industry, placing it in the top 36.8%.
Is Rein Therapeutics' Buyback Yield % too high?
Rein Therapeutics' current Buyback Yield % is -3.65. Based on the distribution chart, Rein Therapeutics ranks #273 out of 741 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rein Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' Buyback Yield % compare to IBIO and RANI?
According to the Biotechnology industry distribution chart, Rein Therapeutics ranks #273 out of 741 companies for Buyback Yield %. This puts Rein Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Rein Therapeutics and its competitors. Rein Therapeutics's current Buyback Yield % is -3.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current Buyback Yield % of -3.65. The current Buyback Yield % is -3.65. Rein Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current Buyback Yield % is -3.65 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rein Therapeutics Business Description

Address 12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
30GF Score

Get the complete analysis for RNTX

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price